204 related articles for article (PubMed ID: 15571479)
1. Which drug combination for colorectal cancer?
Doggrell SA
Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479
[TBL] [Abstract][Full Text] [Related]
2. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
3. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
5. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
7. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
10. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
12. [Biotherapy in colorectal cancer].
Des Guetz G
J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
[TBL] [Abstract][Full Text] [Related]
13. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
14. The role of new agents in the treatment of colorectal cancer.
Folprecht G; Köhne CH
Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
[TBL] [Abstract][Full Text] [Related]
15. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
17. Second line therapies move to the forefront in colorectal cancer.
Miller M
J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
[No Abstract] [Full Text] [Related]
18. Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Douillard JY
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S34-7. PubMed ID: 15871764
[TBL] [Abstract][Full Text] [Related]
19. The role of bevacizumab as first-line therapy for colon cancer.
Marshall J
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
[TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]